ClinicalTrials.gg
CompletedNCT02723630Updated Mar 14, 2019Results posted

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

A Phase 1 interventional study of Lenvatinib 10 mg in Healthy Volunteers, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-14.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This will be a randomized, single dose, open-label, three-treatment period crossover study in healthy participants to determine whether 2 test lots of 10-mg capsules that vary by the level of lenvatinib Type-C crystal are bioequivalent to a reference lot of 10-mg capsules.

Read the detailed description

The study will consist of 2 phases: Prerandomization and Randomization. The Prerandomization Phase will have 2 periods: Screening and Baseline. The Randomization Phase will consist of three 6-day long Treatment Periods with each Treatment Period separated by a 1-day long Baseline. Sixty participants will be evenly randomized to 1 of 6 possible treatment sequences (A, B, C, D, E, or F). The 3 treatments vary by the level of crystalline polymorph Type-C present in the drug product batch used in each arm, respectively: Treatment 1 - low Type-C crystal level less than 12%; Treatment 2 - reference Type-C crystal level 12% to 26%; and Treatment 3 - high Type-C crystal level greater than 26%.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Bioequivalence
  • Lenvatinib
  • Healthy Volunteers
  • Lenvima
  • E7080
03

In context

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female participants age greater than or equal to 18 years and less than or equal to 55 years old
  2. Nonsmokers or smokers who smoke no more than 10 cigarettes per day
  3. greater than or equal to 18 and less than or equal to 32 kg/m2 at Screening
  4. Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin)
  5. All females will be considered to be of unless they are (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)
  6. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of (e.g., total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double-barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
  7. Male participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.
  8. Provide written

Exclusion criteria

Exclusion Criteria:

  1. illness that requires medical treatment within 8 weeks of Screening or a clinically significant infection that requires medical treatment within 4 weeks of dosing
  2. Evidence of disease that may influence the outcome of the study within 4 weeks prior to dosing, e.g., psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
  3. Any history of GI surgery that may affect pharmacokinetic profiles of lenvatinib e.g., hepatectomy, nephrotomy, digestive organ resection known at Screening or Baseline
  4. Any clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, findings, or laboratory test results that require medical treatment at Screening or Baseline
  5. Blood pressure measurements of greater than 150/90 mm Hg. Confirmation should be obtained by performing three measurements (at least 5 minutes apart) to yield a mean value. Participants may be enrolled if they are on a stable dose of a single antihypertensive drug at least 30 days prior to the first dose of study drug and do not intend to change the dose or drug during the study.
  6. A prolonged interval (QTcF greater than 450 ms) demonstrated on ECG at Screening or Baseline
  7. Known history of clinically significant drug allergy at Screening or Baseline
  8. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening or Baseline or with a known history of sensitivity to any of the components of the test products
  9. Known to be positive at Screening
  10. Active viral hepatitis (A, B, or C) as demonstrated by positive serology at Screening
  11. History of drug or alcohol dependency or abuse within the 2 years prior to Screening or a positive urine drug test at Screening or Baseline
  12. Intake of grapefruit or grapefruit-containing beverages or food within 72 hours prior to dosing
  13. Intake of medications known to be strong inhibitors or inducers of CYP450 3A4 metabolizing enzymes within 2 weeks prior to dosing
  14. Currently enrolled in another clinical trial or used any drug or device within 30 days preceding
  15. Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week of dosing
  16. Engagement in strenuous exercise within 2 weeks prior to check-in (e.g., marathon runners, weight lifters)
  17. Any condition that would make the participant, in the opinion of the investigator or sponsor unsuitable for the study or not likely to complete the study for any reason
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Sequence A:

    Participants will receive one dose of Treatment 1 followed by one dose of Treatment 2, then one dose of Treatment 3

    Drug: Lenvatinib 10 mg

  • Experimental
    Sequence B

    Participants will receive one dose of Treatment 2, followed by one dose of Treatment 3, then one dose of Treatment 1

    Drug: Lenvatinib 10 mg

  • Experimental
    Sequence C

    Participants will receive one dose of Treatment 3, followed by one dose of Treatment 1, then one dose of Treatment 2

    Drug: Lenvatinib 10 mg

  • Experimental
    Sequence D

    Participants will receive one dose of Treatment 3, followed by one dose of Treatment 2, then one dose of Treatment 1

    Drug: Lenvatinib 10 mg

  • Experimental
    Sequence E

    Participants will receive one dose of Treatment 1, followed by one dose of Treatment 3, then one dose of Treatment 2

    Drug: Lenvatinib 10 mg

  • Experimental
    Sequence F

    Participants will receive one dose of Treatment 2, followed by one dose of Treatment 1, then one dose of Treatment 3

    Drug: Lenvatinib 10 mg

Interventions

  • Treatment 1: low Type-C crystal level \<12% Treatment 2: reference\* Type-C crystal level 12% to 26% Treatment 3: high Type-C crystal level \>26%

    Also known as: E7080;Lenvima

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t))

    Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) methodology using a previously validated assay. The lower limit of quantitation (LLOQ) for the assay was 0.25 ng/mL. AUC(0-t) was calculated by the linear-up log-down trapezoidal method. No concentration estimates were provided for missing sample values. Any sample with a missing value was treated as if the sample had not been scheduled for collection.

    Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose

  2. Area Under the Concentration-Time Curve From Zero Time (Predose) Extrapolated to Infinite Time (AUC(0-inf))

    Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL. AUC(0-t) was calculated by the linear-up log-down trapezoidal method. AUC(0-inf) was calculate as follows; (AUC(0-inf)) = (AUC(0-t)) + (Ct/Kel), where Ct is the last measurable drug concentration and Kel is the elimination rate constant. The apparent first-order Kel was estimated, when possible, from the slope of the regression line for the terminal ln-linear concentration-time values.

    Time frame: Periods 1, 2, and 3; 0 (Predose), 2, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose.

  3. Area Under the Concentration-Time Curve From Zero Time (Predose) to 24 Hours (AUC(0-24))

    Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

    Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, and 24 hours postdose

Secondary outcomes

  1. Area Under the Concentration-Time Curve From Zero Time (Predose) to 72 Hours (AUC(0-72))

    Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

    Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, and 72 hours postdose

  2. Maximum Observed Concentration (Cmax) of Lenvatinib in Plasma

    Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

    Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose

  3. Time to Cmax (Tmax) for Lenvatinib

    Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

    Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose

  4. Terminal Elimination Phase Half-life (t1/2)

    Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

    Time frame: Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose

  5. Number of Participants With Non-Serious Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events as a Measure of Safety and Tolerability of Lenvatinib

    Safety assessments consisted of monitoring and recording all adverse events (AEs) (serious and non-serious); regular monitoring of hematology, blood chemistry and urine values; periodic measurement of vital signs and electrocardiograms, performance of physical examinations. A TEAE was defined as an AE that emerges during treatment, having been absent at pretreatment (Baseline), or reemerges during treatment, having been present at pretreatment but stopped before treatment, or worsens in severity during treatment relative to the pretreatment state, when the AE is continuous. TEAEs considered by the investigator to be possibly or probably related to study drug, or TEAEs with missing causality, were included.

    Time frame: From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 months

07

Results

Posted Mar 14, 2019

Participant flow

Intervention Period 1
Participant flow — Intervention Period 1
MilestoneSequence ASequence BSequence CSequence DSequence ESequence F
Started101010101010
Completed91010101010
Not completed100000
Withdrew: Adverse event100000
Intervention Period 2
Participant flow — Intervention Period 2
MilestoneSequence ASequence BSequence CSequence DSequence ESequence F
Started91010101010
Completed91010101010
Not completed000000
Intervention Period 3
Participant flow — Intervention Period 3
MilestoneSequence ASequence BSequence CSequence DSequence ESequence F
Started91010101010
Completed9910101010
Not completed010000
Withdrew: Consumption of restricted item010000

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t))

Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) methodology using a previously validated assay. The lower limit of quantitation (LLOQ) for the assay was 0.25 ng/mL. AUC(0-t) was calculated by the linear-up log-down trapezoidal method. No concentration estimates were provided for missing sample values. Any sample with a missing value was treated as if the sample had not been scheduled for collection.

Time frame:
Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose
Reported as:
Geometric mean · ng·hr/mL
Area Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t))
ng·hr/mLTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
Area Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t))1010 ± 40.41010 ± 36.9965 ± 39.3
Statistical analysis
  • Treatment 1: Low Crystal Form vs Treatment 2: Reference Crystal Form · Mixed Models Analysis · p = 0.8826 (P-value for the formulation) · Geometric least square mean ratio: 100.52 · 90% CI 94.84 to 106.53Geometric LS Mean ratio was back-transformed least squares mean and mean treatment difference.
  • Treatment 2: Reference Crystal Form vs Treatment 3: High Crystal Form · Mixed Models Analysis · p = 0.1095 (P-value for formulation) · Geometric least squares mean ratio: 96.03 · 90% CI 92.11 to 100.12Geometric LS Mean ratio was back-transformed least squares mean and mean treatment difference.
PrimaryArea Under the Concentration-Time Curve From Zero Time (Predose) Extrapolated to Infinite Time (AUC(0-inf))

Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL. AUC(0-t) was calculated by the linear-up log-down trapezoidal method. AUC(0-inf) was calculate as follows; (AUC(0-inf)) = (AUC(0-t)) + (Ct/Kel), where Ct is the last measurable drug concentration and Kel is the elimination rate constant. The apparent first-order Kel was estimated, when possible, from the slope of the regression line for the terminal ln-linear concentration-time values.

Time frame:
Periods 1, 2, and 3; 0 (Predose), 2, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose.
Reported as:
Geometric mean · ng·hr/mL
Area Under the Concentration-Time Curve From Zero Time (Predose) Extrapolated to Infinite Time (AUC(0-inf))
ng·hr/mLTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
Area Under the Concentration-Time Curve From Zero Time (Predose) Extrapolated to Infinite Time (AUC(0-inf))1030 ± 40.01020 ± 36.9991 ± 39.0
Statistical analysis
  • Treatment 1: Low Crystal Form vs Treatment 2: Reference Crystal Form · Mixed Models Analysis · p = 0.8121 (P value for formulation) · Geometric least squares mean ratio: 100.80 · 90% CI 95.31 to 106.61Geometric LS Mean ratio was back-transformed least squares mean and treatment difference mean
  • Treatment 2: Reference Crystal Form vs Treatment 3: High Crystal Form · Mixed Models Analysis · p = 0.1630 (P value for formulation) · Geometric least squares mean ratio: 96.51 · 90% CI 92.53 to 100.65Geometric LS Mean ratio was back-transformed least squares mean and treatment difference mean
PrimaryArea Under the Concentration-Time Curve From Zero Time (Predose) to 24 Hours (AUC(0-24))

Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

Time frame:
Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · ng·hr/mL
Area Under the Concentration-Time Curve From Zero Time (Predose) to 24 Hours (AUC(0-24))
ng·hr/mLTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
Area Under the Concentration-Time Curve From Zero Time (Predose) to 24 Hours (AUC(0-24))791 ± 47.4792 ± 39.2740 ± 43.5
Statistical analysis
  • Treatment 1: Low Crystal Form vs Treatment 2: Reference Crystal Form · Mixed Models Analysis · p = 0.9427 (P value for formulation) · Geometric least squares mean ratio: 99.68 · 90% CI 92.45 to 107.47Geometric LS Mean ratio was back-transformed least squares mean and treatment difference mean
  • Treatment 2: Reference Crystal Form vs Treatment 3: High Crystal Form · Mixed Models Analysis · p = 0.0403 (P value for formulation) · Geometric least squares mean ratio: 93.50 · 90% CI 88.63 to 98.64Geometric LS Mean ratio was back-transformed least squares mean and treatment difference mean
SecondaryArea Under the Concentration-Time Curve From Zero Time (Predose) to 72 Hours (AUC(0-72))

Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

Time frame:
Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Geometric mean · ng·hr/mL
Area Under the Concentration-Time Curve From Zero Time (Predose) to 72 Hours (AUC(0-72))
ng·hr/mLTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
Area Under the Concentration-Time Curve From Zero Time (Predose) to 72 Hours (AUC(0-72))975 ± 40.5971 ± 36.7923 ± 39.4
Statistical analysis
  • Treatment 1: Low Crystal Form vs Treatment 2: Reference Crystal Form · Mixed Models Analysis · p = 0.9373 (P value for formulation) · Geometric least squares mean ratio: 100.29 · 90% CI 94.37 to 106.58Geometric LS Mean ratio was back-transformed least squares mean and treatment difference mean
  • Treatment 2: Reference Crystal Form vs Treatment 3: High Crystal Form · Mixed Models Analysis · p = 0.0682 (P value for formulation) · Geometric least squares mean ratio: 95.17 · 90% CI 91.03 to 99.50Geometric LS Mean ratio was back-transformed least squares mean and treatment difference mean
SecondaryMaximum Observed Concentration (Cmax) of Lenvatinib in Plasma

Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

Time frame:
Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of Lenvatinib in Plasma
ng/mLTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
Maximum Observed Concentration (Cmax) of Lenvatinib in Plasma96.0 ± 64.097.1 ± 49.288.0 ± 57.7
Statistical analysis
  • Treatment 1: Low Crystal Form vs Treatment 2: Reference Crystal Form · Mixed Models Analysis · p = 0.8448 (P value for formulation) · Geometric least squares mean ratio: 98.73 · 90% CI 88.57 to 110.06Geometric Least Squares Mean Ratio was back-transformed least squares mean and treatment difference mean
  • Treatment 2: Reference Crystal Form vs Treatment 3: High Crystal Form · Mixed Models Analysis · p = 0.0498 (P value for formulation) · Geometric least squares mean ratio: 90.64 · 90% CI 83.51 to 98.38Geometric LS Mean ratio was back-transformed least squares mean and treatment difference mean
SecondaryTime to Cmax (Tmax) for Lenvatinib

Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

Time frame:
Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose
Reported as:
Median · Hours
Time to Cmax (Tmax) for Lenvatinib
HoursTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
Time to Cmax (Tmax) for Lenvatinib3.000 (1.00 to 12.00)3.000 (1.00 to 12.02)3.000 (2.00 to 12.02)
SecondaryTerminal Elimination Phase Half-life (t1/2)

Blood samples (6 mL each) were collected at the following time points for each Period: 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. The window for 0 to 12 hours was +/-2 minutes, for 24 hours was +/-5 minutes and for \>24 hours was equal to +/-15 to 60 minutes. Plasma concentrations of lenvatinib were quantified by LC-MS/MS methodology using a previously validated assay. The LLOQ for the assay was 0.25 ng/mL.

Time frame:
Periods 1, 2, and 3; 0 (Predose), 1, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose
Reported as:
Mean · Hours
Terminal Elimination Phase Half-life (t1/2)
HoursTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
Terminal Elimination Phase Half-life (t1/2)24.1 ± 6.8824.2 ± 6.2323.5 ± 6.61
SecondaryNumber of Participants With Non-Serious Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events as a Measure of Safety and Tolerability of Lenvatinib

Safety assessments consisted of monitoring and recording all adverse events (AEs) (serious and non-serious); regular monitoring of hematology, blood chemistry and urine values; periodic measurement of vital signs and electrocardiograms, performance of physical examinations. A TEAE was defined as an AE that emerges during treatment, having been absent at pretreatment (Baseline), or reemerges during treatment, having been present at pretreatment but stopped before treatment, or worsens in severity during treatment relative to the pretreatment state, when the AE is continuous. TEAEs considered by the investigator to be possibly or probably related to study drug, or TEAEs with missing causality, were included.

Time frame:
From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 months
Reported as:
Number · Percentage of participants
Number of Participants With Non-Serious Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events as a Measure of Safety and Tolerability of Lenvatinib
Percentage of participantsTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
TEAEs23.723.720.3
Treatment-related TEAEs18.615.216.9
Severe TEAEs1.6900
Serious TEAEs1.6900

Adverse events

Collected over From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment 1: Low Crystal Form0/59 (0%)1/59 (1.7%)14/59 (23.7%)
Treatment 2: Reference Crystal Form0/59 (0%)0/59 (0%)14/59 (23.7%)
Treatment 3: High Crystal Form0/59 (0%)0/59 (0%)12/59 (20.3%)
Most frequent serious events
Most frequent serious events
EventTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/590/590/59
Most frequent other events
Showing 10 of 41
Most frequent other events
EventTreatment 1: Low Crystal FormTreatment 2: Reference Crystal FormTreatment 3: High Crystal Form
HeadacheNervous system disorders2/594/596/59
Blood pressure increasedInvestigations2/592/591/59
Increased appetiteMetabolism and nutrition disorders2/590/590/59
Burning sensationNervous system disorders2/590/590/59
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/590/592/59
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/592/590/59
PapuleSkin and subcutaneous tissue disorders2/590/590/59
PruritusSkin and subcutaneous tissue disorders2/590/590/59
Abdominal painGastrointestinal disorders0/590/591/59
ConstipationGastrointestinal disorders0/591/590/59

Baseline characteristics

Safety Analysis Set (SAS) included all participants who received at least one dose of study drug and had at least one postdose safety assessment.

Age, Continuous
Age, Continuous(Years)Sequence ASequence BSequence CSequence DSequence ESequence FTotal
Mean45.1 ± 9.5545.1 ± 10.7236.3 ± 13.4140.4 ± 10.8031.7 ± 10.3637.8 ± 12.0639.4 ± 11.77
Sex: Female, Male
Sex: Female, Male(Participants)Sequence ASequence BSequence CSequence DSequence ESequence FTotal
Female43222215
Male67888845
08

Study locations

1 site
  • Las Vegas, Nevada, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2015
First posted
Mar 30, 2016
Start
Jul 2013
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Mar 14, 2019
Last update
Mar 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02723630
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Mar 30, 2016
Start date
Jul 2013
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Mar 14, 2019
Last update
Mar 14, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion